Founded in January 2022, Allogenica is dedicated to developing universal CAR-T cell-therapies to treat cancers, particularly blood cancers such as leukemias and lymphomas. To achieve this goal, Allogenica has developed an innovative bioproduction platform based on allogeneic CAR-T cells.
Merely a few months after inception, Allogenica has successfully completed its first round of fundraising with backing from distinguished investors, including:
Aloem (represented by Jean-Pascal Tranié)
Health Angels Rhône-Alpes (HARA)
Et 33 Californie (represented by Stéphane Legastelois)
Additionally, Allogenica is supported by Bpifrance through « deeptech » and « French Tech Seed » labels, and through a « French Tech émergence » grant of €90,000.
The funds raised will enable Allogenica to advance preclinical research on its CAR-T-candidate in blood cancers, expand its bioproduction platform, and reinforce its pipeline, notably to treat solid cancers.